Choroidal Neovascularization Market: By Product Type, By Treatment, By Diagnosis, By Application, By End Users and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Choroidal Neovascularization Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Intravenous and Intravitreal), By Treatment (Angiogenesis Inhibitors Injection, Photodynamic Therapy, Laser Photocoagulation, Low-dose Radiation Therapy, and Surgery), By Diagnosis (Fluorescein Angiography, Indocyanine Green Angiography, Spectral Domain Optical Coherence Tomography, and Others), By Application (Extreme Myopia, Malignant Myopic Degeneration, and Age-Related Developments), By End Users (Hospitals, Specialty Clinics, Homecare, Others) and Region

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Choroidal Neovascularization Market was valued at US$ 5.8 billion in 2023 and is poised to grow at a CAGR of 6.8% over 2024-2030. Choroidal Neovascularization (CNV) is the formation of new blood vessels in the choroid layer of the eye, which is associated with excessive amounts of vascular endothelial growth factor, and is the common cause of neovascular degenerative maculopathy, and can be exacerbated by extreme myopia, malignant myopic degeneration, or age-related developments. Based on the application type, the malignant myopic degeneration segment is anticipated to dominate the choroidal neovascularization market share over the forecast period.

According to a research report, the estimated number of people with age-related macular degeneration will double by 2050, from 2.07 million to 5.44 million. Increased drug development and growing choroidal neovascularization market demand for hospitals and clinics will act as the growth drivers for the market, whereas complications associated with treatment and unavailability of appropriate treatment might pose as challenges for the market. Higher cases of age-related macular degeneration and increasing use of generic drugs are opportunities for market expansion.

Choroidal Neovascularization Market Key Developments:
  • In March 2022, Intas Pharmaceuticals launched a biosimilar of Ranibizumab, an anti-vascular endothelial growth factor, focused on the treatment of ocular degeneration.
  • In June 2023, the US FDA issued a complete response letter to Regeneron Pharmaceuticals for its BLA filed for wet age-related macular degeneration, diabetic macular, and diabetic retinopathy for Aflibercept (Eylea).

summary download arrow Download Free Sample

Choroidal Neovascularization Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Choroidal Neovascularization Market Dynamics

The increasing prevalence of choroidal neovascularization cases, the increasing aging population, and rising government initiatives for the development of healthcare infrastructure are the major factors for the growth of the choroidal neovascularization market. For instance, in Oct 2021, the FDA gave approval for Bausch Health Companies and Clearside Biomediclas’s Xiperetm for suprachoroidal use in the treatment of macular edema associated with uveitis. Additionally, increasing incidences of lifestyle-associated diseases such as high blood pressure, and diabetes is also supporting the growth of the market. Thus, the increased awareness, research and development for lysosomal storage disorders will lead to the growth of the market within the forecast period.

Choroidal Neovascularization Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 5.8 billion

Market CAGR

6.8%

By Product Type

  • Intravenous
  • Intravitreal

By Treatment Type

  • Angiogenesis Inhibitors Injection
  • Photodynamic Therapy
  • Laser Photocoagulation
  • Low-dose Radiation Therapy
  • Surgery

By Diagnosis

  • Fluorescein Angiography
  • Indocyanine Green Angiography
  • Spectral Domain Optical Coherence Tomography
  • Others

By Application

  • Extreme Myopia
  • Malignant Myopic Degeneration
  • Age-Related Developments

By End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Key Features of the Report

  • The choroidal neovascularization market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The Choroidal Neovascularization market was valued at US$ 5.8 billion in 2022 and is expected to grow at a 6.8% CAGR over the forecast period 2023 – 2029.

Higher cases of age-related macular degeneration and increasing use of generic drugs are the key opportunities for the Choroidal Neovascularization market.

Increased drug development and growing demand for hospitals and clinics are the growth drivers in the Choroidal Neovascularization market.

Bausch Health Companies Inc., Bayer AG, Gilead Sciences, Inc., Roche AG, MaaT Pharma, Novartis AG, Pfizer Inc., Quark Pharmaceuticals Inc., and Regeneron Pharmaceuticals Inc. are a few companies operating in the Choroidal Neovascularization market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Choroidal Neovascularization Market Introduction 
2.1.Global Choroidal Neovascularization Market  - Taxonomy
2.2.Global Choroidal Neovascularization Market  - Definitions
2.2.1.Product Type
2.2.2.Treatment Type
2.2.3.Diagnosis
2.2.4.Application
2.2.5.Region
3.Global Choroidal Neovascularization Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Choroidal Neovascularization Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Choroidal Neovascularization Market  By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Intravenous
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Intravitreal
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Choroidal Neovascularization Market  By Treatment Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Angiogenesis Inhibitors Injection
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Photodynamic Therapy
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Laser Photocoagulation
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Low-dose Radiation Therapy
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Surgery
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Choroidal Neovascularization Market  By Diagnosis, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Fluorescein Angiography
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Indocyanine Green Angiography
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Spectral Domain Optical Coherence Tomography
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Choroidal Neovascularization Market  By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Extreme Myopia
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Malignant Myopic Degeneration
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Age-Related Developments
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Choroidal Neovascularization Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Choroidal Neovascularization Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Intravenous
10.1.2.Intravitreal
10.2.  Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Angiogenesis Inhibitors Injection
10.2.2.Photodynamic Therapy
10.2.3.Laser Photocoagulation
10.2.4.Low-dose Radiation Therapy
10.2.5.Surgery
10.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Fluorescein Angiography
10.3.2.Indocyanine Green Angiography
10.3.3.Spectral Domain Optical Coherence Tomography
10.3.4.Others
10.4.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Extreme Myopia
10.4.2.Malignant Myopic Degeneration
10.4.3.Age-Related Developments
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Choroidal Neovascularization Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Intravenous
11.1.2.Intravitreal
11.2.  Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Angiogenesis Inhibitors Injection
11.2.2.Photodynamic Therapy
11.2.3.Laser Photocoagulation
11.2.4.Low-dose Radiation Therapy
11.2.5.Surgery
11.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Fluorescein Angiography
11.3.2.Indocyanine Green Angiography
11.3.3.Spectral Domain Optical Coherence Tomography
11.3.4.Others
11.4.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Extreme Myopia
11.4.2.Malignant Myopic Degeneration
11.4.3.Age-Related Developments
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Choroidal Neovascularization Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Intravenous
12.1.2.Intravitreal
12.2.  Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Angiogenesis Inhibitors Injection
12.2.2.Photodynamic Therapy
12.2.3.Laser Photocoagulation
12.2.4.Low-dose Radiation Therapy
12.2.5.Surgery
12.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Fluorescein Angiography
12.3.2.Indocyanine Green Angiography
12.3.3.Spectral Domain Optical Coherence Tomography
12.3.4.Others
12.4.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Extreme Myopia
12.4.2.Malignant Myopic Degeneration
12.4.3.Age-Related Developments
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Choroidal Neovascularization Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Intravenous
13.1.2.Intravitreal
13.2.  Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Angiogenesis Inhibitors Injection
13.2.2.Photodynamic Therapy
13.2.3.Laser Photocoagulation
13.2.4.Low-dose Radiation Therapy
13.2.5.Surgery
13.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Fluorescein Angiography
13.3.2.Indocyanine Green Angiography
13.3.3.Spectral Domain Optical Coherence Tomography
13.3.4.Others
13.4.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Extreme Myopia
13.4.2.Malignant Myopic Degeneration
13.4.3.Age-Related Developments
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Choroidal Neovascularization Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Intravenous
14.1.2.Intravitreal
14.2.  Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Angiogenesis Inhibitors Injection
14.2.2.Photodynamic Therapy
14.2.3.Laser Photocoagulation
14.2.4.Low-dose Radiation Therapy
14.2.5.Surgery
14.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Fluorescein Angiography
14.3.2.Indocyanine Green Angiography
14.3.3.Spectral Domain Optical Coherence Tomography
14.3.4.Others
14.4.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Extreme Myopia
14.4.2.Malignant Myopic Degeneration
14.4.3.Age-Related Developments
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Bausch Health Companies Inc.
15.2.2.Bayer AG
15.2.3.Intas Pharmaceuticals
15.2.4.Gilead Sciences, Inc.
15.2.5.Roche AG
15.2.6.MaaT Pharma
15.2.7.Novartis AG
15.2.8.Pfizer Inc.
15.2.9.Quark Pharmaceuticals Inc.
15.2.10.Regeneron Pharmaceuticals Inc.
15.2.11.Sanwa Kagaku Kenkyusho Co. Ltd.
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Bausch Health Companies Inc.
  • Bayer AG
  • Intas Pharmaceuticals
  • Gilead Sciences, Inc.
  • Roche AG
  • MaaT Pharma
  • Novartis AG
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanwa Kagaku Kenkyusho Co. Ltd.

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market